Observational studies of psychiatric diseases such as schizophrenia, bipolar disorder and major depression have long tied ...

A new medical study out of Johns Hopkins Children's Center could potentially be a game changer for those suffering certain ...

A new study published in Nature Mental Health has found that people with a higher genetic risk for schizophrenia tend to have ...

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be answered about scalability and costs, experts say.

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

Cobenfy (xanomeline-trospium chloride) was approved for the treatment of adults with schizophrenia in 2024. Cobenfy is the first medicine approved for the treatment of schizophrenia that works ...

A clear, consistent and emotionally neutral approach is often more effective over time than trying to persuade or plead.

Most people with schizophrenia are diagnosed before age 40. But soon, adults ages 65 or older will make up more than 25 percent of people with schizophrenia, research suggests. [1] [2] ...

Early signs of schizophrenia include behavioral, emotional, and cognitive changes. Early diagnosis and treatment can improve outcomes. Learn symptoms and support options.

Schizophrenia affects up to an estimated 2.4 million adults in the United States, yet remains widely misunderstood by the general public and insufficiently treated.

The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...